BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3103932)

  • 1. Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU.
    Villar A; Asensio F; Candel M; Delgado F; Garcia J; Lledó S; Redón J; Roig JV; Sanchez A; Sanchis C
    Chemioterapia; 1987 Feb; 6(1):57-62. PubMed ID: 3103932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Cancer Treat Rep; 1986 Apr; 70(4):481-5. PubMed ID: 3516397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
    Schnitzler G; Queisser W; Heim ME; König H; Katz R; Fritze D; Herrmann R; Arnold H; Henss H; Trux FA
    Cancer Treat Rep; 1986 Apr; 70(4):477-9. PubMed ID: 3516396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
    Cocconi G; DeLisi V; Di Blasio B
    Cancer Treat Rep; 1982 Jun; 66(6):1263-6. PubMed ID: 7083233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group.
    Moertel CG; Lavin PT
    Cancer Treat Rep; 1979; 63(11-12):1863-9. PubMed ID: 393381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
    Faedi M; Amadori M; Gentilini P; Ridolfi R; Ravaioli A; Amadori D; Biserni R; Bonaguri C
    Chemioterapia; 1986 Aug; 5(4):240-3. PubMed ID: 3769045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
    Miyamoto H; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Ikeda K; Usui N; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1160-4. PubMed ID: 6408998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
    Lipton A; Harvey HA; Santen RJ; Stryker JA; Barnes SG; Walker BK; Dixon RH; Givant EM; Bartholomew MJ; Nadjafi C
    Eur J Surg Oncol; 1990 Feb; 16(1):12-4. PubMed ID: 2307239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Matsushiro T; Nimura Y; Nagakawa T; Nakayama T; Yamauchi H; Ogata Y; Shimada H; Miyakawa S; Yamaguchi A; Sakoda K; Yasuda H; Tsukada K; Yoshida K; Ashida H; Ishikawa Y; Kotoura Y; Kinoshita H; Kajiwara T; Watanabe G; Uchimura M; Funabiki T; Ikeda S; Okada S
    Gan To Kagaku Ryoho; 1996 May; 23(6):707-14. PubMed ID: 8645022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combination of 5-fluorouracil, epirubicin and mitomycin C (FEM) on advanced gastric carcinoma.
    Itoh T; Sakata Y; Tamura Y; Furukohori N; Saitoh S; Suzuki H; Tsushima K; Munakata A; Yoshida Y; Takagi S
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1551-6. PubMed ID: 2509606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group.
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Recent Results Cancer Res; 1988; 110():212-8. PubMed ID: 3136519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.